Sree Rayalaseema Hi-Strength Hypo Ltd
SRHHYPOLTDSree Rayalaseema Hi-Strength Hypo Ltd is cheap for a reason. The P/E sits at the 33rd percentile of its own range, and the quarters are still getting worse.
The sharpest disagreement: the P/E sits at the 33rd percentile of its own range, but the engine is deteriorating — cheap for a reason until the quarters turn.
The price is in a downtrend (44 weeks in) while the P/E sits at the 33rd percentile of its own 10-year range. Underneath, the last four quarters read deteriorating — profit −9.1% year on year, and 95% of the last 3 years' profit arrived as cash. What settles it: whether the quarters turn before the discount closes.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Sree Rayalaseema Hi-Strength Hypo Ltd trades at ₹484, in a downtrend and 44 weeks into that stage. That is −4.4% against its own 200-day average. It sits at 36% of a 52-week range of ₹407 to ₹622. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (8 weeks and counting).
Today the stock is in a downtrend — week 44 of stage 4, confirmed. At ₹484 it trades −4.4% versus its 200-day average and sits at 36% of its 52-week range (₹407–₹622).
Against the market, two honest reads. Cumulative: over the last 10.4 years the stock moved +745% while the NIFTY 500 moved +276% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (8 weeks and counting; last ahead the week of 2026-06-19) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Sree Rayalaseema Hi-Strength Hypo Ltd trades at 8.3× P/E, near the bottom of its own range — cheaper only 33% of the time. Its long-run median P/E is 9.5×, measured across 10.3 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 8.3× is near the bottom of its own range — cheaper only 33% of the time, against a long-run median of 9.5× measured over 10.3 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +0.1% against a −21.9% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 5y, of the +7.4%/yr price move, ~+10.6%/yr came from earnings growth and ~−3.2 pp from the multiple (compressing); over 10y, of the +16.3%/yr price move, ~+13.5%/yr came from earnings growth and ~+2.8 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.
A quarterly PEG curve, which only the second data source carries, is not drawn on this page: its two data sources do not share enough overlapping reported history to be compared. A figure nobody could check is not used to price growth — the gap is a decision, not missing data.
Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Sree Rayalaseema Hi-Strength Hypo Ltd reads as mixed on its fundamental arc. Mixed — no clean majority across the growth curves, ROCE slipping at 14.0% — the per-curve reads carry the story. The read is built from 10 quarters across 3 curves, on partial evidence.
Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +4.5% | −26.1% | −6.0% | +6.3% |
| Profit | +3.4% | −16.4% | +8.1% | +13.7% |
| EPS | +0.1% | −16.4% | +8.3% | +11.9% |
| Share price | −21.9% | −12.6% | +7.4% | +16.3% |
4-Factor Sector Score
47.5/100 — rank 5 of 9 in Chemicals - Inorganic · 77% evidence confidence
Sree Rayalaseema Hi-Strength Hypo Ltd scores 47.5 out of 100 against the 9 companies it is compared with in Chemicals - Inorganic, ranking 5. Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity.
The four contributions add to the total exactly: 15.3 + 11.5 + 14.3 + 6.4 = 47.5. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Sree Rayalaseema Hi-Strength Hypo Ltd reported ₹163 Cr of revenue in the Mar 26 quarter, +1.9% year on year. That is the 4th straight quarter of year-on-year growth. Over 10 years it has compounded at 6.3% a year. The last full year, FY26, came in at ₹667 Cr. The last four reported quarters add to ₹666 Cr.
FY26 revenue came in at ₹667 Cr (+4.5% on the year), capping 10 years at 6.3% compound. The latest quarter (Mar 26) printed ₹163 Cr, +1.9% year on year — the 4th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +4.4% growth against the decade's 6.3% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +4.6% over the last 4 quarters against −12.4%/yr over the last 8 — accelerating; TTM profit +1.1% vs +6.1%/yr — rolling over.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Sree Rayalaseema Hi-Strength Hypo Ltd's operating margin is 8.0% in the Mar 26 quarter, −3.0 percentage points against the same quarter a year ago. Across 9 fiscal years the operating margin has ranged 11.0% to 15.0%. The current quarter is running below every full year in that window.
The latest quarter's operating margin is 8.0%, −3.0 pp against the same quarter a year ago. Across 9 fiscal years the operating margin has ranged 11.0%–15.0%.
🚨 Why the margin moved: operating margin went −2.8 pp year on year while gross margin went +3.0 pp — the loss came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Sree Rayalaseema Hi-Strength Hypo Ltd earned ₹20.0 Cr of net profit in the Mar 26 quarter, −9.1% year on year. Full-year FY26 profit was ₹90.0 Cr. The 10-year compound rate is 13.7%. That is 12.3% of the quarter's revenue. The same quarter a year earlier earned ₹22.0 Cr.
Mar 26 profit was ₹20.0 Cr, −9.1% year on year. On the full year, FY26 printed ₹90.0 Cr (+3.4%), and the 10-year compound rate is 13.7%.
🚨 Why profit moved: revenue contributed +1.9% and the margin −3.0 pp — the quarter was revenue-led despite a thinner margin.
Pace comparison, last four quarters: profit +1.9% vs revenue +4.4%. Profit and revenue are moving roughly in step.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 95% of Sree Rayalaseema Hi-Strength Hypo Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹39.0 Cr of operating cash against ₹90.0 Cr of profit. After ₹4.0 Cr of capital spending, ₹35.0 Cr was left as free cash.
FY26: operating cash of ₹39.0 Cr against reported profit of ₹90.0 Cr, leaving free cash of ₹35.0 Cr after ₹4.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 95% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 95%: the cash cycle stretched 31 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving.
Router verdict: the bigger cash user is investment — capital spending ran 1.5× depreciation over three years, so the next section's job is to check what that build-out is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Sree Rayalaseema Hi-Strength Hypo Ltd's cash conversion cycle runs 88 days in FY26, up from 57 days in FY21. Capital spending ran ₹38.0 Cr over the last 3 years. At FY26 sales of ₹667 Cr each day of that cycle holds about ₹1.8 Cr, so roughly ₹161 Cr sits inside the business at any moment.
FY26: debtors at 46 days, inventory at 55 days — roughly 1.8 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 88 days, looser than FY21's 57.
The full loop: cash goes out to suppliers and production on day 0; stock waits 55 days to sell; customers pay about 46 days after that; and suppliers themselves are paid at 13 days — netting out to the 88-day cycle.
In money terms: at FY26 sales of ₹667 Cr, each day of the cycle holds about ₹1.8 Cr — so the 88-day loop keeps roughly ₹161 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹38.0 Cr over the last 3 fiscal years against ₹25.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹0.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.⚠ unverified
Sree Rayalaseema Hi-Strength Hypo Ltd earns a ROCE of 14% in FY26. That is up from a trough of 4% in FY17. Return on invested capital clears the cost of that capital by −1.7 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 13.5% net margin on 0.60× asset turns.
FY26 ROCE is 14%, recovered from a FY17 trough of 4% — the full ladder below shows the fall and the climb, undoctored.
🚨 Why the return is what it is — the wiring (FY26): 13.5% net margin × 0.60× asset turns × 1.15× balance-sheet leverage ≈ 9.3% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 10.3% − 12.0% = a −1.7 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.⚠ unverified
Sree Rayalaseema Hi-Strength Hypo Ltd carries total debt of ₹12.0 Cr against shareholder equity of ₹984 Cr as of Mar 26, a debt-to-equity of 0.01 — effectively unlevered. On the annual view that ratio went from 0.05 in FY22 to 0.01 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of ₹12.0 Cr against shareholder equity of ₹984 Cr — a debt-to-equity of 0.01. On the annual view, debt-to-equity went from 0.05 (FY22) to 0.01 (FY26). The returns on this page are earned, not borrowed.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
No holder of Sree Rayalaseema Hi-Strength Hypo Ltd moved a full percentage point over the last two years — the register is quiet. Promoters moved +0.0 points over the same window, to 61.8%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Foreign institutions: −0.5 points over 8 quarters to 0.1%; Promoters: +0.0 points over 8 quarters to 61.8%; Domestic institutions: +0.0 points over 8 quarters to 0.1%.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Sree Rayalaseema Hi-Strength Hypo Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Indo Borax & Chemicals LtdINDOBORAX | 66.5/100Favorable setup83% evidence | LEADER | 23.4/35 Revenue 22.7% · PAT 19.1% · OPM change 0 pp 83% evidence | 17.6/25 ROCE 15.4% · OPM 20% 95% evidence | 6.6/20 P/E 33.1× · PEG — 50% evidence | 18.9/20 RS sector 23% · RS bench 32.3% · 1Y 29.8%12 of 12 weeks ahead 100% evidence |
| Exact sum: 23.4 + 17.6 + 6.6 + 18.9 = 66.5 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Tanfac Industries LtdTANFACIND | 54.5/100Mixed-positive evidence82% evidence | BREAKING OUT | 10.8/35 Revenue 13.2% · PAT -29.2% · OPM change -1 pp 95% evidence | 18.5/25 ROCE 23.7% · OPM 15% 76% evidence | 6.2/20 P/E 96.1× · PEG — 50% evidence | 19.0/20 RS sector 28.4% · RS bench 38.1% · 1Y 39.2%9 of 12 weeks ahead 100% evidence |
| Exact sum: 10.8 + 18.5 + 6.2 + 19 = 54.5 · Decision use: Price leads the evidence: RS versus the benchmark is 38.1%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 3J.G.Chemicals LtdJGCHEM | 53.0/100Mixed-positive evidence70% evidence | TURNING | 17.4/35 Revenue 14.6% · PAT 1.5% · OPM change -1 pp 83% evidence | 14.3/25 ROCE 18.1% · OPM 8% 95% evidence | 10.4/20 P/E 30× · PEG — 15% evidence | 10.9/20 RS sector -3.5% · RS bench 22.9% · 1Y 6.1%10 of 10 weeks ahead 70% evidence |
| Exact sum: 17.4 + 14.3 + 10.4 + 10.9 = 53 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Ganesh Benzoplast LtdGANESHBE | 49.5/100Mixed-negative evidence62% evidence | TURNING | 11.7/35 Revenue 9.6% · PAT 97.3% · OPM change -14 pp 62% evidence | 14.3/25 ROCE 14.6% · OPM 18% 95% evidence | 11.1/20 P/E 12.1× · PEG — 15% evidence | 12.4/20 RS sector -2.3% · RS bench 23.2% · 1Y 16.7%9 of 11 weeks ahead 70% evidence |
| Exact sum: 11.7 + 14.3 + 11.1 + 12.4 = 49.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Sree Rayalaseema Hi-Strength Hypo Ltdthis pageSRHHYPOLTD | 47.5/100Mixed-negative evidence77% evidence | ASLEEP | 15.3/35 Revenue 4.5% · PAT 1.1% · OPM change -3 pp 83% evidence | 11.5/25 ROCE 14% · OPM 8% 95% evidence | 14.3/20 P/E 8.3× · PEG — 50% evidence | 6.4/20 RS sector -11.3% · RS bench -6.9% · 1Y -24.5%6 of 10 weeks ahead 70% evidence |
| Exact sum: 15.3 + 11.5 + 14.3 + 6.4 = 47.5 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 6Deepak Nitrite LtdDEEPAKNTR | 45.7/100Mixed-negative evidence96% evidence | ASLEEP | 14.6/35 Revenue -4.8% · PAT -20.9% · OPM change 3 pp 88% evidence | 8.8/25 ROCE 11.4% · OPM 18% 100% evidence | 15.2/20 P/E 41.1× · PEG 0.61 100% evidence | 7.1/20 RS sector -8.5% · RS bench -1.6% · 1Y -12.6%9 of 12 weeks ahead 100% evidence |
| Exact sum: 14.6 + 8.8 + 15.2 + 7.1 = 45.7 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 7Fischer Medical Ventures LtdFISCHER | 42.1/100Mixed-negative evidence73% evidence | TURNING | 25.1/35 Revenue 100% · PAT 100% · OPM change -4.1 pp 88% evidence | 5.1/25 ROCE 11.4% · OPM 1% 100% evidence | 8.9/20 P/E 82.6× · PEG — 15% evidence | 3.0/20 RS sector -35.6% · RS bench -32.9% · 1Y -58.8%0 of 11 weeks ahead 70% evidence |
| Exact sum: 25.1 + 5.1 + 8.9 + 3 = 42.1 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -35.6% and the one-year return is -58.8%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 8Archean Chemical Industries LtdACI | 26.6/100Adverse evidence100% evidence | ASLEEP | 4.3/35 Revenue -0.4% · PAT -39.9% · OPM change -6 pp 100% evidence | 7.3/25 ROCE 7.4% · OPM 21% 100% evidence | 12.7/20 P/E 67× · PEG 0.83 100% evidence | 2.3/20 RS sector -17.9% · RS bench -11.7% · 1Y -22.4%0 of 12 weeks ahead 100% evidence |
| Exact sum: 4.3 + 7.3 + 12.7 + 2.3 = 26.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9POCL Enterprises Ltd539195 | 49.2/100Thin evidence · provisional48% evidence | ASLEEP | 18.7/35 Revenue — · PAT — · OPM change 0 pp 17% evidence | 17.6/25 ROCE 26.4% · OPM 5% 76% evidence | 10.8/20 P/E 12.8× · PEG — 15% evidence | 2.1/20 RS sector -19.4% · RS bench -13.7% · 1Y -29.4%2 of 12 weeks ahead 100% evidence |
| Exact sum: 18.7 + 17.6 + 10.8 + 2.1 = 49.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Sree Rayalaseema Hi-Strength Hypo Ltd's share price today?
Sree Rayalaseema Hi-Strength Hypo Ltd trades at ₹484, −21.9% over the past year. The company is valued at ₹831 Cr. The stock sits at 36% of its 52-week range of ₹407–₹622, −4.4% versus its 200-day average. On the tape, the price is in a downtrend, 44 weeks in. — as of 31 July 2026.
What were Sree Rayalaseema Hi-Strength Hypo Ltd's latest quarterly results?
Sree Rayalaseema Hi-Strength Hypo Ltd reported revenue of ₹163 Cr and net profit of ₹20.0 Cr for the Mar 26 quarter. Revenue rose 1.9% and profit fell 9.1% year on year. Earnings per share were ₹11.69. The operating margin was 8.0%, 3.0 pp lower than a year earlier. — as of 31 July 2026.
What is Sree Rayalaseema Hi-Strength Hypo Ltd's revenue?
Sree Rayalaseema Hi-Strength Hypo Ltd reported revenue of ₹163 Cr in the Mar 26 quarter, +1.9% year on year. For the full FY26 fiscal year, revenue was ₹667 Cr (+4.5%). Over the last 10 years revenue compounded at 6.3% a year. — as of 31 July 2026.
What is Sree Rayalaseema Hi-Strength Hypo Ltd's profit?
Sree Rayalaseema Hi-Strength Hypo Ltd earned ₹20.0 Cr of net profit in the Mar 26 quarter, −9.1% year on year. Full-year FY26 profit was ₹90.0 Cr. The operating margin ran 8.0% in the latest quarter. — as of 31 July 2026.
What is Sree Rayalaseema Hi-Strength Hypo Ltd's market cap?
Sree Rayalaseema Hi-Strength Hypo Ltd's market capitalisation is ₹831 Cr at a share price of ₹484. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 31 July 2026.
What is Sree Rayalaseema Hi-Strength Hypo Ltd's P/E ratio?
Sree Rayalaseema Hi-Strength Hypo Ltd trades at a P/E of 8.3×, at the 33rd percentile of its own 10-year range, against a long-run median of 9.5×. This is a comparison with the stock's own history, not a value call — as of 31 July 2026.
Does Sree Rayalaseema Hi-Strength Hypo Ltd pay a dividend?
Yes — Sree Rayalaseema Hi-Strength Hypo Ltd's dividend payout was 6% of profit in FY26, and it recorded a payout in each of its last 9 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 31 July 2026.
Is Sree Rayalaseema Hi-Strength Hypo Ltd overvalued?
On its own history, Sree Rayalaseema Hi-Strength Hypo Ltd looks cheap against its own history: its P/E of 8.3× has been cheaper only 33% of the time in 10 years (long-run median 9.5×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 31 July 2026.
Is Sree Rayalaseema Hi-Strength Hypo Ltd growing?
Not right now — Sree Rayalaseema Hi-Strength Hypo Ltd's latest numbers are shrinking: latest-quarter revenue +1.9% year on year, profit −9.1%, and the margin −3.0 pp at 8.0%. The 10-year compound rates are 6.3% (revenue) and 13.7% (profit). The earnings engine currently reads: deteriorating — as of 31 July 2026.
How is Sree Rayalaseema Hi-Strength Hypo Ltd performing?
Sree Rayalaseema Hi-Strength Hypo Ltd is in a downtrend, 44 weeks in. Its latest quarter's revenue rose 1.9% and profit fell 9.1% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 8 weeks. This describes what the data did, not a rating. — as of 31 July 2026.
What stage is Sree Rayalaseema Hi-Strength Hypo Ltd in?
Mixed — no clean majority across the growth curves, ROCE slipping at 14.0% — the per-curve reads carry the story. The read comes from the last 12 quarters of growth (revenue growth +1.9% latest, profit growth −9.1% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 31 July 2026.
Is Sree Rayalaseema Hi-Strength Hypo Ltd in an uptrend?
No — the price is in a downtrend (week 44 of stage 4), trading −4.4% versus its 200-day average and at 36% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 31 July 2026.
Is Sree Rayalaseema Hi-Strength Hypo Ltd beating the market?
Not lately — on a trailing-13-week view Sree Rayalaseema Hi-Strength Hypo Ltd is currently behind the NIFTY 500 (8 weeks and counting; last ahead the week of 2026-06-19), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.4 years the stock moved +745% against the NIFTY 500's +276% — ahead of the index over the full window. — as of 31 July 2026.
Will Sree Rayalaseema Hi-Strength Hypo Ltd's share price go up?
This page publishes no price forecast for Sree Rayalaseema Hi-Strength Hypo Ltd. What it measures instead: the share price is ₹484, the price is in a downtrend 44 weeks in. Its P/E of 8.3× sits at the 33rd percentile of its own 10-year range. — as of 31 July 2026.
Who owns Sree Rayalaseema Hi-Strength Hypo Ltd?
Promoters hold 61.8% of Sree Rayalaseema Hi-Strength Hypo Ltd, foreign institutions 0.1%, domestic institutions 0.1% and the public 38.1% (latest quarter). No holder moved a full point over the last two years — the register is quiet. — as of 31 July 2026.
Does Sree Rayalaseema Hi-Strength Hypo Ltd have too much debt?
No — Sree Rayalaseema Hi-Strength Hypo Ltd's debt-to-equity is 0.01, and operating profit covers the interest bill 44×. FY26 borrowings were ₹12.0 Cr against equity of ₹971 Cr. The returns on this page are earned, not borrowed — as of 31 July 2026.
What is Sree Rayalaseema Hi-Strength Hypo Ltd's capex?
Sree Rayalaseema Hi-Strength Hypo Ltd spent ₹38.0 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹4.0 Cr, with ₹0.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 31 July 2026.
What is Sree Rayalaseema Hi-Strength Hypo Ltd's cash flow?
Sree Rayalaseema Hi-Strength Hypo Ltd generated ₹39.0 Cr of operating cash flow in FY26 and ₹35.0 Cr of free cash flow after ₹4.0 Cr of capital spending. Reported profit that year was ₹90.0 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 31 July 2026.
Is Sree Rayalaseema Hi-Strength Hypo Ltd's profit real cash?
Yes — over the last 3 fiscal years, 95% of Sree Rayalaseema Hi-Strength Hypo Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹39.0 Cr against reported profit of ₹90.0 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 31 July 2026.
Where is Sree Rayalaseema Hi-Strength Hypo Ltd in its business cycle?
Sree Rayalaseema Hi-Strength Hypo Ltd's FY26 operating margin was 13.0%, against a 9-year band of 11.0%–15.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 8.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 31 July 2026.
What could break the Sree Rayalaseema Hi-Strength Hypo Ltd story?
The sharpest disagreement: the P/E sits at the 33rd percentile of its own range, but the engine is deteriorating — cheap for a reason until the quarters turn. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 31 July 2026.
Is Sree Rayalaseema Hi-Strength Hypo Ltd a stock worth studying right now?
This is not investment advice. The machine read: Sree Rayalaseema Hi-Strength Hypo Ltd is cheap for a reason. The P/E sits at the 33rd percentile of its own range, and the quarters are still getting worse. The sharpest open question: whether the quarters turn before the discount closes. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 31 July 2026.